About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR).

Authors : Relinde I. Y. Lieverse, Evert J. Van Limbergen, Cary J. G. Oberije, Esther G. C. Troost, Sine R. Hadrup, Anne-Marie C. Dingemans, Lizza E. L. Hendriks, Franziska Eckert, Crispin Hiley, Christophe Dooms, Yolande Lievens, Monique C. de Jong, Johan Bussink, Xavier Geets, Vincenzo Valentini, Giuliano Elia, Dario Neri, Charlotte Billiet, Amir Abdollahi, David Pasquier, Pierre Boisselier, Ala Yaromina, Dirk De Ruysscher, Ludwig J. Dubois & Philippe Lambin

The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED‐B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED‐B and has shown therapeutic potential when combined with cytokines, such as IL‐2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED‐B targeting for the imaging and treatment of various types of cancer. ED‐B‐centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody‐based targeted therapies.

Authors : Relinde I. Y. Lieverse Damiënne Marcus Alexander M. A. van der Wiel Evert J. Van Limbergen Jan Theys Ala Yaromina Philippe Lambin Ludwig J. Dubois

Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy

Authors :  PhilippeLambin MD PhD,  Relinde I.Y.Lieverse MD, Franziska Eckert MD , Damiënne Marcus MSc, Cary Oberije PhD, Alexander M.A.van der Wiel MSc, Chandan Guha MD PhD, Ludwig J. Dubois PhD , Joseph O. Deasy PhD

Our opinion is to redesign a new framework in a way radiotherapy is delivered to interact most optimally with immunotherapy rather than directly killing as many cells as possible with radiation.

Authors : Philippe Lambin, Relinde Lieverse

Int J Radiat Oncol Biol Phys. 2018 Jun 1

Authors : Jaffray DA, Das S, Jacobs PM, Jeraj R, Lambin P.

Radiol Med. 2018 Apr

Authors : Cusumano D, Dinapoli N, Boldrini L, Chiloiro G, Gatta R, Masciocchi C, Lenkowicz J, Casà C, Damiani A, Azario L, Van Soest J, Dekker A, Lambin P, De Spirito M, Valentini V.

Acta Oncol. 2018 Apr

Authors : Ureba A, Lindblom E, Dasu A, Uhrdin J, Even AJG, van Elmpt W, Lambin P, Wersäll P, Toma-Dasu I.

IEEE Trans Med Imaging. 2018 Apr

Authors : Apeke S, Gaubert L, Boussion N, Lambin P, Visvikis D, Rodin V, Redou P.

Br J Radiol. 2018 Mar

Authors : Leijenaar RT, Bogowicz M, Jochems A, Hoebers FJ, Wesseling FW, Huang SH, Chan B, Waldron JN, O’Sullivan B, Rietveld D, Leemans CR, Brakenhoff RH, Riesterer O, Tanadini-Lang S, Guckenberger M, Ikenberg K, Lambin P.

PLoS One. 2018 Mar 1

Authors : Carvalho S, Leijenaar RTH, Troost EGC, van Timmeren JE, Oberije C, van Elmpt W, de Geus-Oei LF, Bussink J, Lambin P.

Acta Oncol. 2018 Feb

Authors : Jochems A, El-Naqa I, Kessler M, Mayo CS, Jolly S, Matuszak M, Faivre-Finn C, Price G, Holloway L, Vinod S, Field M, Barakat MS, Thwaites D, de Ruysscher D, Dekker A, Lambin P.

Seizure. 2018 Feb

Authors : Eekers DBP, Pijnappel EN, Schijns OEMG, Colon A, Hoeben A, Zindler JD, Postma AA, Hoffmann AL, Lambin P, Troost EGC.

Cancers (Basel). 2018 Feb 18

Authors : Walsh S, Roelofs E, Kuess P, van Wijk Y, Vanneste B, Dekker A, Lambin P, Jones B, Georg D, Verhaegen F.

Oncotarget. 2018 Feb 15

Authors : Baum RP, Kulkarni HR, Singh A, Kaemmerer D, Mueller D, Prasad V, Hommann M, Robiller FC, Niepsch K, Franz H, Jochems A, Lambin P, Hörsch D.

Oncoimmunology. 2018 Jan 16

Authors : Rekers NH, Olivo Pimentel V, Yaromina A, Lieuwes NG, Biemans R, Zegers CML, Germeraad WTV, Van Limbergen EJ, Neri D, Dubois LJ, Lambin P

Ann Oncol. 2017 Dec 1

Authors : Saini SK, Rekers N, Hadrup SR

Clin Transl Radiat Oncol. 2017 Nov

Authors : Eekers DBP, In ‘t Ven L, Deprez S, Jacobi L, Roelofs E, Hoeben A, Lambin P, de Ruysscher D, Troost EGC.

Br J Radiol. 2017 Aug

Authors : Van Limbergen EJ, De Ruysscher DK, Olivo Pimentel V, Marcus D, Berbee M, Hoeben A, Rekers N, Theys J, Yaromina A, Dubois LJ, Lambin P

Ecancermedicalscience. 2016 Nov 10

Authors : Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A

Radiother Oncol. 2015 Sep

Authors : Rekers NH, Zegers CM, Yaromina A, Lieuwes NG, Biemans R, Senden-Gijsbers BL, Losen M, Van Limbergen EJ, Germeraad WT, Neri D, Dubois L, Lambin P

Clin Cancer Res. 2015 Mar 1

Authors : Zegers CM, Rekers NH, Quaden DH, Lieuwes NG, Yaromina A, Germeraad WT, Wieten L, Biessen EA, Boon L, Neri D, Troost EG, Dubois LJ, Lambin P

Cancer Radiother. 2014 Oct

Authors : Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P